After announcing a deal with Recipharm for development of two inhaled drugs (TRB-1 and TRB-2) earlier this year, Transpire Bio says that it has signed an agreement with the CDMO for development of an additional two inhaled products. Under the new agreement, Recipharm will provide development services for Transpire's TRB-3 and TRB-4 inhaled therapeutics for the … [Read more...] about Transpire Bio contracts with Recipharm for development of two more inhaled drugs
Products and Services
Vectura gets go-ahead to build new facility for its Inhalation Centre of Excellence
According to inhalation CDMO Vectura, the company been granted planning permission to build a new £58 million, 10,000 sq m facility in Southwest England to house the company's Inhalation Centre of Excellence, with construction expected to be completed in 2025. The company said that it aims for the building on the Bristol & Bath Science Park to receive a BREEAM … [Read more...] about Vectura gets go-ahead to build new facility for its Inhalation Centre of Excellence
Nanopharm and Fluidda team up to help inhaled drug developers pursue the alternative bioequivalence pathway
OINDP development specialist Nanopharm, which was acquired by Aptar Pharma in 2019, and functional respiratory imaging (FRI) company Fluidda are teaming up to help sponsors of ANDAs for inhaled drugs for asthma and COPD avoid the need for clinical end-point studies by pursuing the alternative bioequivalence pathway. Sponsors of 505(b)(2) NDAs for inhaled drugs and … [Read more...] about Nanopharm and Fluidda team up to help inhaled drug developers pursue the alternative bioequivalence pathway
MedPharm to provide development services for Mosanna’s MOS-118 potassium channel blocker nasal spray for sleep apnea
CDMO MedPharm has announced that it will provide formulation and delivery development services for Swiss startup Mosanna Therapeutics' MOS-118 potassium channel blocker, with the goal of advancing a nasal spray formulation into clinical development for the treatment of metabolic obstructive sleep apnea (MOSA). Mosanna was formed recently to develop MOS-118 (formerly … [Read more...] about MedPharm to provide development services for Mosanna’s MOS-118 potassium channel blocker nasal spray for sleep apnea
H&T Presspart partners with OzUK on MDI development services
Device maker H&T Presspart has partnered with CRO OzUK in order to offer complete development services for metered dose inhalers to H&T Presspart customers. OzUK, which specializes in MDIs and other liquid-based OINDPs, will provide formulation and testing services in conjunction with delivery device development services offered out of H&T Presspart's … [Read more...] about H&T Presspart partners with OzUK on MDI development services
Copley Scientific launches EnviroMate environmental control chamber for OINDP testing
OINDP testing equipment maker Copley Scientific has announced the launch of the EnviroMate benchtop environmental control chamber, which is designed to reduce variability in OINDP testing that can occur due to inconsistent temperature, humidity, and electrostatic conditions. The chamber allows for DDU and APSD testing in a controlled environment without the need for a … [Read more...] about Copley Scientific launches EnviroMate environmental control chamber for OINDP testing
Nemera opens new headquarters
Device maker Nemera has announced the opening of its new headquarters building in Lyons, France. According to the company, the new BREEAM-certified building will also be home to the company's European innovation teams. Nemera also has an innovation center located in the US. The company develops and manufactures a wide range of OINDPs, including nasal spray pumps, … [Read more...] about Nemera opens new headquarters
Aptar Pharma acquires HF specialist Metaphase Design Group
Aptar Pharma said that it has acquired US-based design firm Metaphase Design Group and will integrate the company into its subsidiary Noble, which Aptar acquired in 2019. Noble launched its Human Factors Plus (HF+) services for combination product development in 2021, and Aptar Pharma says that Metaphase's capabilities will complement Noble's offerings. Metaphase … [Read more...] about Aptar Pharma acquires HF specialist Metaphase Design Group
Ceapro expands collaboration with McMaster University on development of inhaled yeast beta glucans
Canadian biotech Ceapro announced the expansion of an existing collaboration with McMaster University for development of inhaled yeast beta glucans for the prevention and treatment of lung fibrosis caused by COVID-19. According to Ceapro, the team has already successfully created inhalable yeast beta glucan particles via PGX and now plans to optimize delivery and … [Read more...] about Ceapro expands collaboration with McMaster University on development of inhaled yeast beta glucans
Innovate UK awards £1 million grant to Acu-Flow for development of Nebu-Flow technology
The University of Glasgow announced that Innovate UK has awarded a university spinout, Acu-Flow, £1 million for development of the company's Nebu-Flow surface acoustic wave nebulizer technology. The University said that its researchers will work with Acu-Flow and the NIHR Devices for Dignity Med-tech Cooperative to have a working nebulizer ready for manufacturing … [Read more...] about Innovate UK awards £1 million grant to Acu-Flow for development of Nebu-Flow technology